United Therapeutics Corporation (UTHR) FCF Payout Ratio: N/A
The FCF payout ratio for United Therapeutics Corporation (UTHR) is N/A.
UTHR FCF Payout Ratio Chart
UTHR FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
FCF PAYOUT RATIO AVG TTM
N/A
FCF PAYOUT RATIO AVG 3Y
N/A
FCF PAYOUT RATIO AVG 5Y
N/A
FCF PAYOUT RATIO AVG 10Y
N/A
FCF PAYOUT RATIO AVG 15Y
N/A
FCF PAYOUT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Payout Ratio Comparison
FCF Payout Ratio
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
3.95%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $1.04B | $0 | 0.0% |
| 2024 | $1.08B | $0 | 0.0% |
| 2023 | $747.60M | $0 | 0.0% |
| 2022 | $663.70M | $0 | 0.0% |
| 2021 | $477.40M | $0 | 0.0% |
| 2020 | $696.40M | $0 | 0.0% |
| 2019 | ($290.30M) | $0 | N/A (Loss) |
| 2018 | $594.00M | $0 | 0.0% |
| 2017 | $387.90M | $0 | 0.0% |
| 2016 | $600.40M | $0 | 0.0% |
| 2015 | $333.01M | $0 | 0.0% |
| 2014 | $307.86M | $0 | 0.0% |
| 2013 | $393.36M | $0 | 0.0% |
| 2012 | $211.72M | $0 | 0.0% |
| 2011 | $214.22M | $0 | 0.0% |
| 2010 | $192.89M | $0 | 0.0% |
| 2009 | $2.22M | $0 | 0.0% |
| 2008 | ($173.59M) | $0 | N/A (Loss) |
| 2007 | $10.43M | $29.60M | 284.0% |
| 2006 | $36.15M | $0 | 0.0% |
| 2005 | $37.58M | $0 | 0.0% |
| 2004 | $15.56M | $0 | 0.0% |
| 2003 | ($15.57M) | $0 | N/A (Loss) |
| 2002 | ($25.84M) | $0 | N/A (Loss) |
| 2001 | ($39.59M) | $0 | N/A (Loss) |
| 2000 | ($31.75M) | $0 | N/A (Loss) |
| 1999 | ($26.00M) | $0 | N/A (Loss) |
| 1998 | ($10.60M) | $0 | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
United Therapeutics Corporation FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2007-12-31 | 283.97% |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt